{
  "abstract": null,
  "abstract_shown": false,
  "affiliations": [
    "Imperial Cancer Research Fund/Richard Dimbleby Department of Cancer Research, St Thomas`s Hospital, London SE1 7EH",
    "Zumutor Biologics, Bangalore, India",
    "Zumutor Biologics Pvt Ltd, Bangalore, India",
    "1Zumutor Biologics Pvt Ltd, Bangalore, Karnataka, India",
    "NEXT Oncology, San Antonio, TX, USA",
    "NEXT Oncology, Austin, TX, USA",
    "Dana-Farber Cancer Institute, Boston, MA, USA"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Ignacio Garcia-Ribas"
    },
    {
      "affs": [
        1
      ],
      "name": "Maloy Ghosh"
    },
    {
      "affs": [
        2
      ],
      "name": "Sanghamitra Bhattacharjee"
    },
    {
      "affs": [
        1
      ],
      "name": "Yogendra Manjunath"
    },
    {
      "affs": [
        3
      ],
      "name": "Jyotsna Fuloria"
    },
    {
      "affs": [
        4
      ],
      "name": "Ismael Rodriguez Rivera"
    },
    {
      "affs": [
        5
      ],
      "name": "Andrae L Vandross"
    },
    {
      "affs": [
        6
      ],
      "name": "Glenn J Hanna"
    },
    {
      "affs": [
        2
      ],
      "name": "Ashvini Kumar Dubey"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/099ehcmagd7hh.bib",
  "cited_by": 0,
  "doi": "10.1136/jitc-2026-sitc2026.0548",
  "fulltext_url": null,
  "id": "099ehcmagd7hh",
  "issns": [
    "2051-1426"
  ],
  "landing_url": "https://doi.org/10.1136/jitc-2026-sitc2026.0548",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC254-282"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7225311288",
  "pdf_url": "https://jitc.bmj.com/content/14/Suppl_2/A612.full.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-06",
  "publisher": "BMJ Publishing Group",
  "ris": "https://research.draconitic.com/paper/099ehcmagd7hh.ris",
  "sources": [
    {
      "first_seen": "2026-11-07T14:21:08Z",
      "native_id": "8a3a9c8cd59e482b854c0819d1c031cd",
      "source": "doaj",
      "url": "https://doi.org/10.1136/jitc-2026-sitc2026.0548"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors",
  "title_text": "548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors",
  "type": "peer-reviewed",
  "updated_at": "2026-11-08T14:20:35Z",
  "url": "https://research.draconitic.com/paper/099ehcmagd7hh",
  "venue": "Journal for ImmunoTherapy of Cancer",
  "versions": []
}